|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Molecular Genetics |
Departments of Neurosurgery (K.T., M.K., S.S., T.K., N.S., and Y.U.) and Tumor Genetics and Biology (H.S.), Kumamoto University Medical School, Kumamoto; and Department of Neurosurgery (J.K.), Faculty of Medicine, Kagoshima University, Kagoshima; Japan
2 Address correspondence to Kenji Tada, Department of Neurosurgery, Kumamoto University Medical School, 1-1-1 Honjo, Kumamoto 860-8556, Japan (ktada{at}fc.kuh.kumamoto-u.ac.jp).
Abstract
Neurofibromatosis 1 (NF1) is an autosomal dominant disorder that predisposes sufferers to various forms of neoplasia. Among affected individuals, 15%-20% develop astrocytomas, especially pilocytic astrocytomas (PA), which are benign and classified as grade I by the World Health Organization. They are generally well circumscribed, and their progression is slow. NF1-associated PAs (NF1-PAs) occasionally behave as aggressive tumors. To elucidate underlying genetic events in clinically progressive NF1-PAs, we performed molecular genetic analysis on 12 PAs, including 3 NF1-PAs, for p53, p16, and epidermal growth factor receptor genes, as well as loss of heterozygosity (LOH) on chromosome 1p, 10, 17, and 19q. None of the obvious genetic alterations typically seen in higher grade astrocytomas were found in 9 sporadic PAs. However, in 2 of 3 NF1-PAs, microsatellite analysis showed LOH10, including the PTEN (phosphatase and tensin homolog deleted on chromosome 10) gene locus, despite the diagnosis of pilocytic astrocytoma; one of these also manifested homozygous deletion of the p16 gene. The other NF1-PA harbored only LOH of the NF1 gene locus (17q). Our preliminary results support the hypothesis that some NF1-PAs differ genetically from sporadic PAs.
References
Bajenaru, M.L., Zhu, Y., Hedrick, N.M., Donahoe, J., Parada, L.F.,
and Gutmann, D.H. (2002) Astrocyte-specific inactivation of the
neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation.
Mol. Cell Biol. 22,5100
-5113.
Cairncross, J.G., Ueki, K., Zlatescu, M.C., Lisle, D.K.,
Finkelstein, D.M., Hammond, R.R., Silver, J.S., Stark, P.C., Macdonald, D.R.,
Ino, Y., Ramsay, D.A., and Louis, D.N. (1998) Specific genetic
predictors of chemotherapeutic response and survival in patients with
anaplastic oligodendrogliomas. J. Natl. Cancer Inst.
90,1473
-1479.
Cantley, L.C., and Neel, B.G. (1999) New insights into
tumor suppression: PTEN suppresses tumor formation by restraining the
phosphoinositide 3-kinase/Akt pathway. Proc. Natl. Acad. Sci.
USA 96,4240
-4245.
Cawthon, R.M., Weiss, R., Xu, G.F., Viskochil, D., Culver, M., Stevens, J., Robertson, M., Dunn, D., Gesteland, R., O'Connell, P., and White, R. (1990) A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 62,193 -201.[CrossRef][ISI][Medline]
Cheng, Y., Pang, J.C.S., Ng, H.K., Ding, M., Zhang, S.F., Zheng, J., Liu, D.G., and Poon, W.S. (2000) Pilocytic astrocytomas do not show most of the genetic changes commonly seen in diffuse astrocytomas. Histopathology 37,437 -444.[CrossRef][ISI][Medline]
Cohen, B.H., Kaplan, A.M., and Packer, R.J. (1990-1991) Management of intracranial neoplasms in children with neurofibromatosis type 1 and 2. The Children's Cancer Study Group. Pediatr. Neurosurg. 16,66 -72.[ISI][Medline]
Daston, M.M., Scrable, H., Nordlund, M., Sturbaum, A.K., Nissen, L.M., and Ratner, N. (1992) The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells and oligodendrocytes. Neuron 8, 415-428.[CrossRef][ISI][Medline]
DeClue, J.E., Cohen, B.D., and Lowy, D.R. (1991)
Identification and characterization of the neurofibromatosis type 1 gene
product. Proc. Natl. Acad. Sci. USA
88,9914
-9918.
Di Cristofano, A., and Pandolfi, P.P. (2000) The multiple roles of PTEN in tumor suppression. Cell 100,387 -390.[CrossRef][ISI][Medline]
Duerr, E.M., Rollbrocker, B., Hayashi, Y., Peters, N., Meyer-Puttlitz, B., Louis, D.N., Schramm, J., Wiestler, O.D., Parsons, R., Eng, C., and von Deimling, A. (1998) PTEN mutations in gliomas and glioneuronal tumors. Oncogene 16,2259 -2264.[CrossRef][ISI][Medline]
Figarella-Branger, D., Daniel, L., Andre, P., Guia, S., Renaud, W.,
Monti, G., Vivier, E., and Rougon, G. (1999) The PEN5 epitope
identifies an oligodendrocyte precursor cell population and pilocytic
astrocytomas. Am. J. Pathol.
155,1261
-1269.
Friedman, J.M., Gutmann, D.H., MacCollin, M., and Riccardi, V.M. (Eds.) (1999) Neurofibromatosis: Phenotype, Natural History and Pathogenesis, 3rd ed., Baltimore, Md.: Johns Hopkins University Press.
Gutmann, D.H., Wood, D.L., and Collins, F.S. (1991)
Identification of the neurofibromatosis type 1 gene product. Proc.
Natl. Acad. Sci. USA 88,9658
-9662.
Gutmann, D.H., Giordano, M.J., Mahadeo, D.K., Lau, N., Silbergeld, D., and Guha, A. (1996) Increased neurofibromatosis 1 gene expression in astrocytic tumors: Positive regulation by p21-ras. Oncogene 12,2121 -2127.[ISI][Medline]
Gutmann, D.H., Aylsworth, A., Carey, J.C., Korf, B., Marks, J., Pyeritz, R.E., Rubenstein, A., and Viskochil, D. (1997) The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278, 51-57.[Abstract]
Gutmann, D.H., Donahoe, J., Brown, T., James, C.D., and Perry, A. (2000) Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas. Neuropathol. Appl. Neurobiol. 26,361 -367.[CrossRef][ISI][Medline]
Gutmann, D.H., Hedrick, N.M., Li, J., Nagarajan, R., Perry, A., and
Watson, M.A. (2002) Comparative gene expression profile analysis
of neurofibromatosis 1-associated and sporadic pilocytic astrocytomas.
Cancer Res. 62,2085
-2091.
Holland, E.C., Celestino, J., Dai, C., Schaefer, L., Sawaya, R.E., and Fuller, G.N. (2000) Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat. Genet. 25,55 -57.[CrossRef][ISI][Medline]
Huson, S.M., and Hughes, R.A.C. (Eds.) (1994) The Neurofibromatoses: A Pathogenetic and Clinical Overview. New York: Chapman and Hall Medical.
Ilgren, E.B., and Stiller, C.A. (1987) Cerebellar astrocytomas. Part II. Pathologic features indicative of malignancy. Clin. Neuropathol. 6,201 -214.[ISI][Medline]
Kamiryo, T., Tada, K., Shiraishi, S., Shinojima, N., Nakamura, H., Kochi, M., Kuratsu, J., Saya, H., and Ushio, Y. (2002) Analysis of homozygous deletion of the p16 gene and correlation with survival in patients with glioblastoma multiforme. J. Neurosurg. 96,815 -822.[CrossRef][ISI][Medline]
Kleihues, P., and Ohgaki, H. (1999) Primary and secondary glioblastomas: From concept to clinical diagnosis. Neuro-Oncology 1,44 -51.[Abstract]
Kleihues, P., and Cavenee, W.K. (Eds.) (2000) Pathology and Genetics of Tumours of the Nervous System (World Health Organization Classification of Tumours). Lyon, France: IARC Press.
Kluwe, L., Hagel, C., Tatagiba, M., Thomas, S., Stavrou, D., Ostertag, H., von Deimling, A., and Mautner, V.F. (2001) Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas. J. Neuropathol. Exp. Neurol. 60,917 -920.[ISI][Medline]
Lau, N., Feldkamp, M.M., Roncari, L., Loehr, A.H., Shannon, P., Gutmann, D.H., and Guha, A. (2000) Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. J. Neuropathol. Exp. Neurol. 59,759 -767.[ISI][Medline]
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S.I.,
Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., Bigner, S.H., Giovanella,
B.C., Ittmann, M., Tycko, B., Hibshoosh, H., Wigler, M.H., and Parsons, R.
(1997) PTEN, a putative protein tyrosine phosphatase gene mutated
in human brain, breast, and prostate cancer. Science
275,1943
-1947.
Li, J., Perry, A., James, C.D., and Gutmann, D.H.
(2001) Cancer-related gene expression profiles in NF1-associated
pilocytic astrocytomas. Neurology
56,885
-890.
Listernick, R., Louis, D.N., Packer, R.J., and Gutmann, D.H. (1997) Optic pathway gliomas in children with neurofibromatosis 1: Consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann. Neurol. 41,143 -149.[CrossRef][ISI][Medline]
Listernick, R., Charrow, J., and Gutmann, D.H. (1999) Intracranial gliomas in neurofibromatosis type 1. Am. J. Med. Genet. 89,38 -44.[CrossRef][ISI][Medline]
Ly, D.H., Lockhart, D.J., Lerner, R.A., and Schultz, P.G.
(2000) Mitotic misregulation and human aging.
Science 287,2486
-2492.
Molloy, P.T., Bilaniuk, L.T., Vaughan, S.N., Needle, M.N., Liu,
G.T., Zackai, E.H., and Phillips, P.C. (1995) Brainstem tumors in
patients with neurofibromatosis type 1: A distinct clinical entity.
Neurology 45,1897
-1902.
Nielsen, G.P., Stemmer-Rachamimov, A.O., Ino, Y., Moller, M.B.,
Rosenberg, A.E., and Louis, D.N. (1999) Malignant transformation
of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16
inactivation. Am. J. Pathol.
155,1879
-1884.
NIH. National Institutes of Health Consensus Development Conference. (1988) Neurofibromatosis: Conference statement. Arch. Neurol. 45,575 -578.[ISI][Medline]
Okutani, T., Okabayashi, Y., Kido, Y., Sugimoto, Y., Sakaguchi, K.,
Matuoka, K., Takenawa, T., and Kasuga, M. (1994) Grb2/Ash binds
directly to tyrosines 1068 and 1086 and indirectly to tyrosine 1148 of
activated human epidermal growth factor receptors in intact cells.
J. Biol. Chem. 269,31310
-31314.
Ruggieri, M., and Packer, R.J. (2001) Why do benign
astrocytomas become malignant in NF1? Neurology
56,827
-829.
Shiraishi, S., Tada, K., Nakamura, H., Makino, K., Kochi, M., Saya, H., Kuratsu, J., and Ushio, Y. (2002) Influence of p53 mutations on prognosis of patients with glioblastoma. Cancer 95,249 -257.[CrossRef][ISI][Medline]
Steck, P.A., Pershouse, M.A., Jasser, S.A., Yung, W.K., Lin, H., Ligon, A.H., Langford, L.A., Baumgard, M.L., Hattier, T., Davis, T., Frye, C., Hu, R., Swedlund, B., Teng, D.H., and Tavtigian, S.V. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15,356 -362.[CrossRef][ISI][Medline]
Tada, K., Shiraishi, S., Kamiryo, T., Nakamura, H., Hirano, H., Kuratsu, J., Kochi, M., Saya, H., and Ushio, Y. (2001) Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: Correlation with patient age and survival. J. Neurosurg. 95,651 -659.[ISI][Medline]
Viskochil, D., Buchberg, A.M., Xu, G., Cawthon, R.M., Stevens, J., Wolff, R.K., Culver, M., Carey, J.C., Copeland, N.G., Jenkins, N.A., White, R., and O'Connell, P. (1990) Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62,187 -192.[CrossRef][ISI][Medline]
Wallace, M.R., Marchuk, D.A., Andersen, L.B., Letcher, R., Odeh,
H.M., Saulino, A.M., Fountain, J.W., Brereton, A., Nicholson, J., Mitchell,
A.L., Brownstein, B.H., and Collins, F.S. (1990) Type 1
neurofibromatosis gene: Identification of a large transcript disrupted in
three NF1 patients [erratum in Science 250, 1749, 1990].
Science 249,181
-186.
Zhu, Y., and Parada, L.F. (2001) Neurofibromin, a tumor suppressor in the nervous system. Exp. Cell Res. 264, 19-28.[CrossRef][ISI][Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
